Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Complete Response Rate at 450 Days 28.6% ?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1345)
•••
Comment by CancerSlayeron Oct 08, 2024 5:52pm
240 Views
Post# 36258529

RE:Complete Response Rate at 450 Days 28.6% ?

RE:Complete Response Rate at 450 Days 28.6% ?
Eoganacht wrote: In the news release it says the 450 day CR rate is 26.5%

This rate represents the 18 out of 68 patients who are CR at 450 days.

But 5 of those 68 patients have not yet reached 450 days so isn't the current CR rate at 450 days actually more like 18 out of 63 patients or 28.6% ?


That's how I see it.  Using our interpretation, TR patients (CR + IR = 72.1%) who had a durable response would also be understated....we would have 19 of 63 patients, or 30%.  The NR also states that the TR patients (reported as 19/68 = 27.9%) had a "duration" of this response for at least "450" days.  However, I believe the response duration (90 to 450 days) should read "360" days...& of course using the 19/63 (30%) figure.  Maybe it's time to restart the presses?  IMHO...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities